{
  "report_rows": [
    {
      "kpi": "Q4 revenue",
      "prediction": "IN-LINE",
      "answer": "pred ~$2.89B vs. cons $2.87B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q4 adjusted diluted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$1.28 vs. cons $1.25",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q4 organic revenue growth",
      "prediction": "IN-LINE",
      "answer": "pred ~7.8% vs. cons 7.6%",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2027 revenue guidance",
      "prediction": "LOWER",
      "answer": "guide ~$11.98B vs. cons $12.05B (FY2027)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2027 adjusted diluted EPS guidance",
      "prediction": "LOWER",
      "answer": "guide ~$5.33 vs. cons $5.49 (FY2027)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "UniFirst closing timetable",
      "prediction": "UNCHANGED",
      "answer": "guide ~2H 2026 vs. cons 2H 2026 (calendar 2026)",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": -4.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": -6.5,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "A modest Q4 EPS beat of ~$1.28 versus $1.25 is unlikely to offset FY2027 EPS guidance of ~$5.33 versus $5.49 consensus; the ~$0.16 out-period reset should drive estimate cuts and valuation de-rating even if core organic growth is near 7.8% versus 7.6%.",
  "day5_confidence": "MEDIUM"
}